Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine

Infection and Immunity

Volumn 67, Issue 2, 1999, Pages 921-927

  Oftung, Fredrik ^a,c   Næss, Lisbeth Meyer ^a   Wetzler, Lee M ^b   Korsvold, Gro Ellen ^a   Aase, Audun ^a   Høiby, E Arne ^a   Dalseg, Rolf ^a   Holst, Johan ^a   Michaelsen, Terje E ^a   Haneberg, Bjørn ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b BOSTON MEDICAL CENTER   (United States)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; MENINGOCOCCUS B OUTER MEMBRANE VESICLE VACCINE; MENINGOCOCCUS VACCINE; POR A ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MALE; MEMBRANE VESICLE; NEISSERIA MENINGITIDIS; NORMAL HUMAN; NORWAY; NOSE SECRETION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PURIFICATION; SERUM BACTERICIDAL ACTIVITY; T LYMPHOCYTE ACTIVATION; VACCINATION;

EID: 0032956104     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.2.921-927.1999     Document Type: Article

References (44)

1. Abbas, A. K., K. M. Murphy, and A. Sher. 1996. Functional diversity of helper T lymphocytes. Nature 383:787-793.
2. Ada, G. L. 1990. The immunological principles of vaccination. Lancet 335: 523-526.
3. Bjune, G., A. Høiby, J. K. Grønnesby, O. Arnesen, J. H. Fredriksen, A. Halstensen, E. Holten, A. K. Lindbak, H. Nøkleby, E. Rosenqvist, L. K. Solberg, O. Closs, J. Eng, L. O. Frøholm, A. Lystad, L. S. Bakketeig, and B. Hareide. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:1093-1096.
4. Blake, M. S., and E. C. Gotschlich. 1982. Purification and partial characterization of the major outer membrane proteins of Neisseria gonorrhoeae. Infect. Immun. 36:277-283.
5. Boslego, J., J. Garcia, C. Cruz, W. Zollinger, B. Brandt, S. Ruiz, M. Martiez, J. Arthur, P. Underwood, W. Silva, E. Moran, W. Hankins, J. Gilly, J. Mays, and the Chilean National Committee for Meningococcal Disease. 1995. Efficacy, safety, and immunogenicity of a meningococcal vaccine group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine 13: 821-829.
6. Claassen, I., J. Meylis, P. van der Ley, C. Peeters, H. Bronst, J. Robert, D. Borsboom, A. van der Ark, I. van Straaten, P. Roholl, B. Kuipers, and J. T. Poolman. 1996. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14:1001-1008.
7. Dalseg, R., J. Holst, T. Tangen, G. Stabbetorp, P. Simonsen, E. Jantzen, B. Haneberg, E. Namork, and L. R. Haaheim. 1996. Outer membrane vesicles from group B meningococci can act as mucosal adjuvant for influenza virus antigens, p. 177-182. In E. Brown, E. Norrby, D. Burton, and J. Mekalanos (ed.), Vaccines 96. Molecular approaches to the control of infectious diseases. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
8. Dalseg, R., E. Wedege, I. L. Haugen, J. Holst, and B. Haneberg. 1995. Group B meningococcal OMV vaccine as a mucosal immunogen. Clin. Immunol. Immunopathol. 76:93.
9. Frasch, C. E. 1995. Meningococcal vaccines, p. 245-283. In K. Cartwright (ed.), Meningococcal disease. John Wiley & Sons, Inc., New York, N.Y.
10. Fredriksen, J. H., E. Rosenqvist, E. Wedege, K. Bryn, L. O. Frøholm, A. K. Lindbak, B. Møgster, E. Namork, E. Rye, G. Stabbetorp, R. Winsnes, B. Aase, and O. Closs. 1991. Production, characterization, and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 14:67-80.
11. Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1307-1326.
12. Gotschlich, E. C. 1984. Meningococcal meningitis, p. 237-244. In E. Germainer (ed.), Bacterial vaccines. Academic Press, Orlando, Fla.
13. Guttormsen, H. K., L. M. Wetzler, and A. Næss. 1993. Humoral immune response to the class 3 outer membrane protein during the course of meningococcal disease. Infect. Immun. 61:4734-4742.
14. Guttormsen, H.-K., L. M. Wetzler, and C. O. Solberg. 1994. Humoral immune response to the class 1 outer membrane protein during the course of meningococcal disease. Infect. Immun. 62:1473-1443.
15. Haneberg, B., R. Dalseg, E. Wedege, E. A. Høiby, I. L. Haugen, F. Oftung, S. R. Andersen, L. M. Næss, A. Aase, T. E. Michaelsen, and J. Holst. 1998. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect. Immun. 66:1334-1341.
16. Høiby, E. A., E. Rosenqvist, L. O. Frøholm, G. Bjune, B. Feiring, H. Nøkleby, and E. Rønnild. 1991. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH Ann. 14:147-156.
17. Levi, R., E. Aboud-Pirak, C. Leclerc, G. H. Lowell, and R. Arnon. 1995. Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes. Vaccine 13:1353-1359.
18. Lowell, G. H., R. W. Kaminsky, S. Grate, R. E. Hunt, C. Charney, S. Zimmer, and C. Colleton. 1996. Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice. Infect. Immun. 64:1706-1713.
19. Lowell, G. H., R. Kaminsky, K. Kersey, T. Vancott, L. Loomis, G. Smith, R. Redfield, D. Freidman, S. Amselem, and D. Birx. 1995. Nasal immunization with HIV gp160 formulated with proteosomes, emulsomes, or cholera toxin B subunit: induction of anti gp160 serum IgA and IgG and intestinal, vaginal, and lung IgA, p. 81. In 2nd National Conference on Human Retroviruses and Related Infections.
20. Lystad, A., and S. Aasen. 1991. The epidemiology of meningococcal disease in Norway 1975-91. NIPH Ann. 14:57-66.
21. Malett, C. P., T. L. Hale, R. W. Kaminsky, T. Larsen, N. Orr, D. Cohen, and G. H. Lowell. 1995. Intranasal and intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection. Infect. Immun. 63:2382-2386.
22. McGhee, J. R., J. Mestecky, M. T. Dertzbaugh, J. H. Eldridge, M. Hirasawa, and H. Kiyono. 1992. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 10:75-88.
23. Melancon, J., R. A. Murgita, and I. W. DeVoe. 1983. Activation of murine B lymphocytes by Neisseria meningitidis and isolated meningococcal surface antigens. Infect. Immun. 42:471-479.
24. Meyer Næss, L., F. Oftung, A. Aase, R. Sandin, L. E. Wetzler, and T. Michaelsen. 1998. Human T cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine. Infect. Immun. 66:959-965.
25. Milagres, L. G., S. R. Ramos, C. T. Sacchi, C. E. A. Melles, V. S. D. Vieira, H. Sato, G. S. Brito, J. C. Moraec, and C. E. Frasch. 1994. Immune response of Brazilian children to a Neisseria meningitis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect. Immun. 62:4419-4424.
26. Peeters, C. C. A. M., H. C. Rümke, L. C. Sundermann, E. M. Rouppe van der Voort, J. Meulenbelt, M. Schuller, A. J. Kuipers, P. van der Ley, and J. T. Poolman. 1996. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 14:1009-1015.
27. Peltola, H. P. H. 1983. Meningococcal disease: still with us. Rev. Infect. Dis. 5:71-91.
28. Perkins, B. A., K. Jonsdottir, H. Briem, E. Griffiths, B. D. Plikaytis, E. A. Høiby, E. Rosenqvist, J. Holst, H. Nøkleby, F. Sotolongo, G. Sierra, C. Huergo, G. M. Carlone, D. Williams, J. Dykes, D. Kapczynski, E. Thikomirov, J. D. Wenger, and C. V. Broome. 1998. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis. 177:683-691.
29. Rosenqvist, E., E. A. Høiby, E. Wedege, K. Bryn, J. Kolberg, A. Klem, E. Rønnild, G. Bjune, and H. Nøkleby. 1995. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. 63:4642-4652.
30. Saukkonen, K. M., M. Leinonen, H. Abdillahi, and J. T. Poolman. 1989. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine 7:325-328.
31. Sierra, G. V. G., H. C. Campa, N. M. Vacacel, I. L. Garcia, P. L. Izquierdo, P. F. Sotolongo, G. V. Casanueva, C. O. Rico, C. R. Rodriguez, and M. H. Terry. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14:195-210.
32. Tsai, C. M. 1986. The analysis of lipopolysaccharide vaccines by silver staining following SDS-polyacrylamide gel electrophoresis. J. Biol. Stand. 14:25-33.
33. van der Voort, E. R., P. van der Ley, J. van der Biezen, S. George, O. Tunnela, H. van Dijken, B. Kuipers, and J. Poolman. 1996. Specificity of human bactericidal antibodies against PorA P1.7, 16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect. Immun. 64: 2745-2751.
34. van der Voort, E. R., H. van Dijken, B. Kuipers, J. van der Biezen, P. van der Ley, J. Meylis, I. Claassen, and J. T. Poolman. 1997. Human B- and T-cell responses after immunization with a hexavalent PorA meningococcal outer membrane vesicle vaccine. Infect. Immun. 65:5184-5190.
35. Walker, R. I. 1994. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 12:387-400.
36. Wedege, E., and L. O. Frøholm. 1986. Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect. Immun. 51:571-578.
37. Wedege, E., E. A. Høiby, E. Rosenqvist, and G. Bjune. 1998. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect. Immun. 66:3223-3231.
38. Wetzler, L. M., Y. Ho, and H. Reiser. 1996. Neisserial porins induce B lymphocytes to express costimulatory B7-2 molecules and to proliferate. J. Exp. Med. 183:1151-1159.
39. Wetzler, L. M., M. S. Blake, K. Barry, and E. C. Gotschlich. 1992. Gonococcal porin vaccine evaluation: comparison of Por proteosomes, liposomes and blebs isolated from rmp deletions mutants. J. Infect. Dis. 166:551-555.
40. Wiertz, E. J. H. J., J. A. M. van Gaans-van den Brink, H. Gausepohl, A. Procknicka-Chalufour, P. Hoogerhout, and J. T. Poolman. 1992. Identification of T cell cpitopes occurring in a meningococcal class 1 outer membrane protein using overlapping peptides assembled with simultaneous multiple peptide synthesis. J. Exp. Med. 176:79-88.
41. Wiertz, E. J. H. J., J. A. M. van Gaans-van den Brink, G. M. T. H. Schreuder, A. A. M. Termijtelen, P. Hoogerhout, and J. T. Poolman. 1991. T cell recognition of Neisseria meningitidis class 1 outer membrane proteins. J. Immunol 147:2012-2018.
42. Williams, M. B., and E. C. Butcher. 1997. Homing of naive and memory T-lymphocyte subsets to Peyer's patches, lymph nodes, and spleen. J. Immunol. 159:1746-1752.
43. Wyle, F. E., M. S. Artenstein, B. L. Brandt, E. C. Tramont, D. L. Kasper, P. L. Altieri, S. L. Berman, and J. P. Lowenthal. 1972. Immunological response in man to group B meningococcal polysaccharide vaccines. J. Infect. Dis. 126:514-522.
44. Zollinger, W., and E. Moran. 1991. Meningococcal vaccines - present and future. Trans. Royal Soc. Trop. Med. Hyg. 85:37-43.